Chiesi completed the acquisition of Deferiprone business from Apotex.

Chiesi Farmaceutici, a research-focused healthcare company, completed the acquisition of ApoPharma's Deferiprone business from Apotex, the parent company of ApoPharma and a pharmaceutical corporation. Financial terms were not disclosed. “Through this transaction, we will remain dedicated to our mission to provide patients affected by this hematological condition with a proven therapeutic option. The addition of Ferriprox® to our portfolio strengthens our offerings to patients and expands our commitment to the rare disease communities around the world. In addition, our presence in Canada represents an entirely new geography for our company and an important milestone in our continued focus on meeting the needs of patients around the world,” Ugo Di Francesco, Chiesi CEO.